EA200900796A1 - Пиперидиновые агонисты gpcr - Google Patents
Пиперидиновые агонисты gpcrInfo
- Publication number
- EA200900796A1 EA200900796A1 EA200900796A EA200900796A EA200900796A1 EA 200900796 A1 EA200900796 A1 EA 200900796A1 EA 200900796 A EA200900796 A EA 200900796A EA 200900796 A EA200900796 A EA 200900796A EA 200900796 A1 EA200900796 A1 EA 200900796A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- gpcr
- пиперидиновые
- агонисты
- obesity
- agonists
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Соединения формулы (I) или их фармацевтически приемлемые соли являются агонистами GPCR (G-белок-сопряженных рецепторов) и полезны для лечения ожирения и диабета.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0700124A GB0700124D0 (en) | 2007-01-04 | 2007-01-04 | GPCR agonists |
GB0708740A GB0708740D0 (en) | 2007-05-08 | 2007-05-08 | Gpcr agonists |
GB0719762A GB0719762D0 (en) | 2007-10-10 | 2007-10-10 | GPCR agonists |
PCT/GB2008/050011 WO2008081205A1 (en) | 2007-01-04 | 2008-01-04 | Piperidine gpcr agonists |
Publications (3)
Publication Number | Publication Date |
---|---|
EA200900796A1 true EA200900796A1 (ru) | 2010-02-26 |
EA015805B1 EA015805B1 (ru) | 2011-12-30 |
EA015805B9 EA015805B9 (ru) | 2012-03-30 |
Family
ID=39203222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200900796A EA015805B9 (ru) | 2007-01-04 | 2008-01-04 | Пиперидиновые агонисты gpcr |
Country Status (28)
Country | Link |
---|---|
US (1) | US20100022591A1 (ru) |
EP (2) | EP2114931B1 (ru) |
JP (1) | JP2010514829A (ru) |
KR (1) | KR20090104092A (ru) |
CN (1) | CN101627036A (ru) |
AR (1) | AR064736A1 (ru) |
AT (1) | ATE531710T1 (ru) |
AU (1) | AU2008203673A1 (ru) |
BR (1) | BRPI0806468A2 (ru) |
CA (1) | CA2674093A1 (ru) |
CL (1) | CL2008000017A1 (ru) |
DK (1) | DK2114931T3 (ru) |
EA (1) | EA015805B9 (ru) |
ES (1) | ES2376015T3 (ru) |
HK (1) | HK1135704A1 (ru) |
HR (1) | HRP20110964T1 (ru) |
IL (1) | IL199680A0 (ru) |
MA (1) | MA31084B1 (ru) |
MX (1) | MX2009007180A (ru) |
NZ (1) | NZ578144A (ru) |
PE (1) | PE20081849A1 (ru) |
PL (1) | PL2114931T3 (ru) |
PT (1) | PT2114931E (ru) |
RS (1) | RS52168B (ru) |
SA (1) | SA08280756B1 (ru) |
SI (1) | SI2114931T1 (ru) |
TW (1) | TWI380818B (ru) |
WO (1) | WO2008081205A1 (ru) |
Families Citing this family (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
US20080312281A1 (en) * | 2004-12-24 | 2008-12-18 | Matthew Colin Thor Fyfe | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes |
NZ564759A (en) * | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
CA2651089C (en) | 2006-05-04 | 2018-02-20 | Peter Sieger | A polymeric form of 1-((4-methyl-quinazolin-2-yl)methyl)-3-7-(2-butyn-1-yl)-8-(3-(r)-aminopiperidin-1-yl)xanthine |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
AR064735A1 (es) * | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
EP2200609A1 (en) | 2007-09-10 | 2010-06-30 | Prosidion Limited | Compounds for the treatment of metabolic disorders |
BRPI0817881A2 (pt) | 2007-10-10 | 2015-03-31 | Novartis Ag | Compostos orgânicos e seus usos |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
GB0812649D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812642D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
GB0812648D0 (en) * | 2008-07-10 | 2008-08-20 | Prosidion Ltd | Compounds |
CN102137844B (zh) | 2008-07-11 | 2013-05-22 | Irm责任有限公司 | 作为gpr119活性调控剂的化合物和组合物 |
UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
BRPI0916997A2 (pt) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | Inibidor de dpp-4 e seu uso |
EP2344195A2 (en) | 2008-09-10 | 2011-07-20 | Boehringer Ingelheim International GmbH | Combination therapy for the treatment of diabetes and related conditions |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
US8865729B2 (en) | 2008-12-23 | 2014-10-21 | Boehringer Ingelheim International Gmbh | Salt forms of a xanthine compound |
AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
GB0904285D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904284D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB0904287D0 (en) | 2009-03-12 | 2009-04-22 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
TW201113269A (en) | 2009-06-24 | 2011-04-16 | Boehringer Ingelheim Int | New compounds, pharmaceutical composition and methods relating thereto |
WO2010149684A1 (en) | 2009-06-24 | 2010-12-29 | Boehringer Ingelheim International Gmbh | New compounds, pharmaceutical composition and methods relating thereto |
EP2464228B1 (en) * | 2009-08-13 | 2017-12-06 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
KR20120107080A (ko) | 2009-11-27 | 2012-09-28 | 베링거 인겔하임 인터내셔날 게엠베하 | 리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료 |
WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2547339A1 (en) | 2010-03-18 | 2013-01-23 | Boehringer Ingelheim International GmbH | Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions |
GB201006166D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
GB201006167D0 (en) | 2010-04-14 | 2010-05-26 | Prosidion Ltd | Compounds for the treatment of metabolic disorders |
ITMI20100770A1 (it) | 2010-05-03 | 2011-11-04 | Dipharma Francis Srl | Procedimento per la preparazione di 3-(4-piridinil)-propanolo e suoi intermedi |
EP2566469B1 (en) | 2010-05-05 | 2022-12-21 | Boehringer Ingelheim International GmbH | Combination therapy |
TW201209054A (en) | 2010-05-28 | 2012-03-01 | Prosidion Ltd | Novel compounds |
ITMI20100984A1 (it) | 2010-05-31 | 2011-12-01 | Dipharma Francis Srl | Procedimento per la preparazione di ossadiazoli |
WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
EP3366304B1 (en) | 2010-06-24 | 2020-05-13 | Boehringer Ingelheim International GmbH | Diabetes therapy |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
AR083904A1 (es) | 2010-11-18 | 2013-04-10 | Prosidion Ltd | Derivados de 1,4-pirrolidinas disustituidos y 3-il-aminas y sus usos en el tratamiento de desordenes metabolicos |
GB201114389D0 (en) | 2011-08-22 | 2011-10-05 | Prosidion Ltd | Novel compounds |
JP6047144B2 (ja) * | 2011-04-08 | 2016-12-21 | メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. | 置換シクロプロピル化合物、このような化合物を含有する組成物および処置方法 |
KR101913619B1 (ko) | 2011-06-09 | 2018-12-28 | 리젠 파마슈티컬스 소시에떼 아노님 | Gpr-119의 조절제로서의 신규한 화합물 |
EP2720544B1 (en) | 2011-06-16 | 2016-12-21 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment |
HUE061596T2 (hu) | 2011-07-15 | 2023-07-28 | Boehringer Ingelheim Int | Szubsztituált dimer kinazolin származék, annak elõállítása és alkalmazása az I. és II. típusú cukorbetegség kezelésére szolgáló gyógyszerkészítményekben |
WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
US9422266B2 (en) | 2011-09-30 | 2016-08-23 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment |
WO2013062838A1 (en) * | 2011-10-24 | 2013-05-02 | Merck Sharp & Dohme Corp. | Substituted piperidinyl compounds useful as gpr119 agonists |
AU2012339870B2 (en) | 2011-11-15 | 2017-06-29 | Merck Sharp & Dohme Corp. | Substituted cyclopropyl compounds useful as GPR119 agonists |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び/又はネフローゼ症候群の治療に用いるdpp−4阻害薬としてのキサンチン誘導体 |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
WO2015128453A1 (en) | 2014-02-28 | 2015-09-03 | Boehringer Ingelheim International Gmbh | Medical use of a dpp-4 inhibitor |
KR101726819B1 (ko) | 2014-10-27 | 2017-04-13 | 동아에스티 주식회사 | Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물 |
AU2017276758A1 (en) | 2016-06-10 | 2018-11-08 | Boehringer Ingelheim International Gmbh | Combinations of Linagliptin and metformin |
EP3421455B1 (en) * | 2017-06-29 | 2019-03-27 | F.I.S.- Fabbrica Italiana Sintetici S.p.A. | Improved process for the preparation of chiral 3-amino-piperidins, useful intermediates for the preparation of tofacitinib |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3576810A (en) * | 1968-06-20 | 1971-04-27 | Robins Co Inc A H | 1-substituted-3-(-4)-aroylpiperidines |
US5252586A (en) * | 1990-09-28 | 1993-10-12 | The Du Pont Merck Pharmaceutical Company | Ether derivatives of alkyl piperidines and pyrrolidines as antipsychotic agents |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
DE4222565A1 (de) * | 1992-07-09 | 1994-01-13 | Hoechst Ag | Meta-substituierte Sechsringaromaten zur Verwendung in Flüssigkristallmischungen |
US6100042A (en) | 1993-03-31 | 2000-08-08 | Cadus Pharmaceutical Corporation | Yeast cells engineered to produce pheromone system protein surrogates, and uses therefor |
DE4311968A1 (de) * | 1993-04-10 | 1994-10-20 | Hoechst Ag | Smektische Flüssigkristallmischung |
DE4311967A1 (de) * | 1993-04-10 | 1994-10-13 | Hoechst Ag | Smektische Flüssigkristallmischung |
US5338738A (en) * | 1993-04-19 | 1994-08-16 | Bristol-Myers Squibb Company | Cerebral function enhancers: acyclic amide derivatives of pyrimidinylpiperidines |
FR2705346B1 (fr) * | 1993-05-18 | 1995-08-11 | Union Pharma Scient Appl | Nouveaux dérivés de pipéridinyl thio indole, leurs procédés de préparation, compositions pharmaceutiques les contenant, utiles notamment comme antalgiques . |
DE69422379T2 (de) | 1993-08-13 | 2000-05-11 | Zeneca Ltd | Thiadiazolderivate und ihre verwendung als fungizide oder insektizide |
WO1997015567A1 (de) * | 1995-10-20 | 1997-05-01 | Dr. Karl Thomae Gmbh | 5-gliedrige heterocyclen, diese verbindungen enthaltende arzneimittel und deren verwendung sowie verfahren zu ihrer herstellung |
ZA977103B (en) * | 1996-08-09 | 1999-02-08 | Eisai Co Ltd | Benzopiperidine derivatives |
GB9719496D0 (en) | 1997-09-13 | 1997-11-19 | Glaxo Group Ltd | G protien chimeras |
AU5700999A (en) | 1998-09-01 | 2000-03-21 | Basf Aktiengesellschaft | Enhanced functional expression of g protein-coupled receptors |
US6221660B1 (en) | 1999-02-22 | 2001-04-24 | Synaptic Pharmaceutical Corporation | DNA encoding SNORF25 receptor |
WO2002042274A1 (fr) * | 2000-11-21 | 2002-05-30 | Mitsubishi Chemical Corporation | Procede de production de 2-(4-pyridyl)ethanethiol |
FR2829027A1 (fr) | 2001-08-29 | 2003-03-07 | Aventis Pharma Sa | Association avec un antagoniste du recepteur cb1, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de parkinson |
FR2829028B1 (fr) | 2001-08-29 | 2004-12-17 | Aventis Pharma Sa | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
CA2457922A1 (en) | 2001-08-31 | 2003-03-13 | University Of Connecticut | Novel pyrazole analogs acting on cannabinoid receptors |
TWI231757B (en) | 2001-09-21 | 2005-05-01 | Solvay Pharm Bv | 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
RU2286988C2 (ru) | 2001-09-21 | 2006-11-10 | Солвей Фармасьютикалс Б.В. | Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью |
HUP0401567A3 (en) | 2001-09-21 | 2005-06-28 | Solvay Pharm Bv | Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them |
FR2831883B1 (fr) | 2001-11-08 | 2004-07-23 | Sanofi Synthelabo | Forme polymorphe du rimonabant, son procede de preparation et les compositions pharmaceutiques en contenant |
SE0104332D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
SE0104330D0 (sv) | 2001-12-19 | 2001-12-19 | Astrazeneca Ab | Therapeutic agents |
FR2833842B1 (fr) | 2001-12-21 | 2004-02-13 | Aventis Pharma Sa | Compositions pharmaceutiques a base de derives d'azetidine |
WO2003063781A2 (en) | 2002-01-29 | 2003-08-07 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
EP1482794A1 (en) | 2002-03-06 | 2004-12-08 | Merck & Co., Inc. | Method of treatment or prevention of obesity |
DE60334787D1 (de) | 2002-03-12 | 2010-12-16 | Merck Sharp & Dohme | Substituierte amide |
AR038966A1 (es) | 2002-03-18 | 2005-02-02 | Solvay Pharm Bv | Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1 |
CA2479618A1 (en) | 2002-03-26 | 2003-10-09 | William K. Hagmann | Spirocyclic amides as cannabinoid receptor modulators |
ES2192494B1 (es) | 2002-03-27 | 2005-02-16 | Consejo Superior De Investigaciones Cientificas | Derivados de 1,2,4-triazol con propiedades cannabinoides. |
US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
WO2003087037A1 (en) | 2002-04-05 | 2003-10-23 | Merck & Co., Inc. | Substituted aryl amides |
FR2838439B1 (fr) | 2002-04-11 | 2005-05-20 | Sanofi Synthelabo | Derives de terphenyle, leur preparation, les compositions pharmaceutqiues en contenant |
FR2838438A1 (fr) | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
ES2301833T3 (es) | 2002-07-29 | 2008-07-01 | Hoffmann La Roche | Derivados de benzodioxol. |
AU2003257145B2 (en) | 2002-08-02 | 2008-11-13 | Merck Sharp & Dohme Corp. | Substituted furo (2,3-b) pyridine derivatives |
US20050101542A1 (en) | 2002-08-20 | 2005-05-12 | Regents Of The University Of California | Combination therapy for controlling appetites |
AR041268A1 (es) | 2002-09-19 | 2005-05-11 | Solvay Pharm Bv | Derivados de la 1h -1,2,4- triazol-3-carboxamida que tienen actividad agonista, agonista parcial, agonista inversa o antagonista del receptor cb 1 de cannabinoide y composiciones farmaceuticas que los contienen |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
WO2004035566A1 (en) | 2002-10-18 | 2004-04-29 | Pfizer Products Inc. | Cannabinoid receptor ligands and uses thereof |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
KR20050088194A (ko) | 2002-12-19 | 2005-09-02 | 머크 앤드 캄파니 인코포레이티드 | 치환된 아미드 |
GB0230087D0 (en) | 2002-12-24 | 2003-01-29 | Astrazeneca Ab | Therapeutic agents |
CN100360527C (zh) | 2003-01-02 | 2008-01-09 | 霍夫曼-拉罗奇有限公司 | Cb1受体反激动剂 |
MXPA05007114A (es) | 2003-01-02 | 2005-08-26 | Hoffmann La Roche | Nuevos agonistas inversos del receptor cb1. |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
DE502004011328D1 (de) | 2003-02-13 | 2010-08-12 | Sanofi Aventis Deutschland | Substituierte hexahydro-pyrazino(1,2-a)pyrimidin-4,7-dionderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
KR20050100686A (ko) | 2003-02-13 | 2005-10-19 | 사노피-아벤티스 도이칠란트 게엠베하 | 질소-치환된헥사하이드로피라지노[1,2-a]피리미딘-4,7-디온 유도체,이의 제조방법 및 의약으로서의 이의 용도 |
US7169797B2 (en) * | 2003-02-14 | 2007-01-30 | Abbott Laboratories | Protein-tyrosine phosphatase inhibitors and uses thereof |
US20040167188A1 (en) * | 2003-02-14 | 2004-08-26 | Zhili Xin | Protein-tyrosine phosphatase inhibitors and uses thereof |
WO2004078261A1 (en) | 2003-03-07 | 2004-09-16 | The University Court Of The University Of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
AR045496A1 (es) * | 2003-08-29 | 2005-11-02 | Schering Corp | Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados |
NZ547965A (en) | 2003-12-24 | 2009-12-24 | Prosidion Ltd | 1,2,4-Oxadiazole derivatives as GPCR receptor agonists |
US20080312281A1 (en) * | 2004-12-24 | 2008-12-18 | Matthew Colin Thor Fyfe | G-Protein Coupled Receptor (Gpr116) Agonists and Use Thereof for Treating Obesity and Diabetes |
EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
GB0428514D0 (en) | 2004-12-31 | 2005-02-09 | Prosidion Ltd | Compounds |
DOP2006000008A (es) * | 2005-01-10 | 2006-08-31 | Arena Pharm Inc | Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1 |
JP2008545008A (ja) | 2005-06-30 | 2008-12-11 | プロシディオン・リミテッド | Gpcrアゴニスト |
JP5114395B2 (ja) | 2005-06-30 | 2013-01-09 | プロシディオン・リミテッド | Gpcrアゴニスト |
EP1909791A1 (en) | 2005-06-30 | 2008-04-16 | Prosidion Limited | G-protein coupled receptor agonists |
NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
WO2007116229A1 (en) * | 2006-04-06 | 2007-10-18 | Prosidion Limited | Heterocyclic gpcr agonists |
MX2009005935A (es) * | 2006-12-06 | 2009-06-30 | Smithkline Beecham Corp | Compuestos biciclicos y su uso como anti-diabeticos. |
BRPI0806312A2 (pt) * | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
AR064735A1 (es) * | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
ES2373181T3 (es) * | 2007-01-04 | 2012-02-01 | Prosidion Ltd | Agonistas de gpcr de piperidina. |
-
2008
- 2008-01-03 AR ARP080100018A patent/AR064736A1/es not_active Application Discontinuation
- 2008-01-03 CL CL200800017A patent/CL2008000017A1/es unknown
- 2008-01-03 PE PE2008000085A patent/PE20081849A1/es not_active Application Discontinuation
- 2008-01-04 WO PCT/GB2008/050011 patent/WO2008081205A1/en active Application Filing
- 2008-01-04 US US12/522,018 patent/US20100022591A1/en not_active Abandoned
- 2008-01-04 BR BRPI0806468-7A patent/BRPI0806468A2/pt not_active IP Right Cessation
- 2008-01-04 SI SI200830517T patent/SI2114931T1/sl unknown
- 2008-01-04 ES ES08700184T patent/ES2376015T3/es active Active
- 2008-01-04 PL PL08700184T patent/PL2114931T3/pl unknown
- 2008-01-04 MX MX2009007180A patent/MX2009007180A/es active IP Right Grant
- 2008-01-04 AT AT08700184T patent/ATE531710T1/de active
- 2008-01-04 PT PT08700184T patent/PT2114931E/pt unknown
- 2008-01-04 DK DK08700184.8T patent/DK2114931T3/da active
- 2008-01-04 JP JP2009544448A patent/JP2010514829A/ja active Pending
- 2008-01-04 RS RS20120031A patent/RS52168B/en unknown
- 2008-01-04 NZ NZ578144A patent/NZ578144A/en not_active IP Right Cessation
- 2008-01-04 EP EP08700184A patent/EP2114931B1/en active Active
- 2008-01-04 CN CN200880007091A patent/CN101627036A/zh active Pending
- 2008-01-04 CA CA002674093A patent/CA2674093A1/en not_active Abandoned
- 2008-01-04 EP EP11172885A patent/EP2383270A1/en not_active Withdrawn
- 2008-01-04 TW TW097100419A patent/TWI380818B/zh not_active IP Right Cessation
- 2008-01-04 AU AU2008203673A patent/AU2008203673A1/en not_active Abandoned
- 2008-01-04 EA EA200900796A patent/EA015805B9/ru not_active IP Right Cessation
- 2008-01-04 KR KR1020097016214A patent/KR20090104092A/ko not_active Application Discontinuation
- 2008-01-05 SA SA8280756A patent/SA08280756B1/ar unknown
-
2009
- 2009-07-02 IL IL199680A patent/IL199680A0/en unknown
- 2009-07-03 MA MA32072A patent/MA31084B1/fr unknown
-
2010
- 2010-04-16 HK HK10103732.5A patent/HK1135704A1/xx not_active IP Right Cessation
-
2011
- 2011-12-21 HR HR20110964T patent/HRP20110964T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010514829A (ja) | 2010-05-06 |
CA2674093A1 (en) | 2008-07-10 |
MX2009007180A (es) | 2009-07-15 |
PL2114931T3 (pl) | 2012-03-30 |
MA31084B1 (fr) | 2010-01-04 |
EP2114931B1 (en) | 2011-11-02 |
PE20081849A1 (es) | 2009-01-26 |
ATE531710T1 (de) | 2011-11-15 |
US20100022591A1 (en) | 2010-01-28 |
TWI380818B (zh) | 2013-01-01 |
DK2114931T3 (da) | 2012-02-13 |
WO2008081205A1 (en) | 2008-07-10 |
HK1135704A1 (en) | 2010-06-11 |
ES2376015T3 (es) | 2012-03-08 |
HRP20110964T1 (hr) | 2012-01-31 |
AU2008203673A1 (en) | 2008-07-10 |
CN101627036A (zh) | 2010-01-13 |
SI2114931T1 (sl) | 2012-02-29 |
IL199680A0 (en) | 2010-04-15 |
SA08280756B1 (ar) | 2011-01-24 |
EA015805B1 (ru) | 2011-12-30 |
EP2114931A1 (en) | 2009-11-11 |
TW200835489A (en) | 2008-09-01 |
RS52168B (en) | 2012-08-31 |
NZ578144A (en) | 2011-03-31 |
EP2383270A1 (en) | 2011-11-02 |
PT2114931E (pt) | 2012-01-12 |
KR20090104092A (ko) | 2009-10-05 |
AR064736A1 (es) | 2009-04-22 |
CL2008000017A1 (es) | 2008-08-01 |
BRPI0806468A2 (pt) | 2011-09-27 |
EA015805B9 (ru) | 2012-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200900796A1 (ru) | Пиперидиновые агонисты gpcr | |
EA200900880A1 (ru) | Пиперидиновые агонисты gpcr | |
EA200900878A1 (ru) | Пиперидиновые агонисты gpcr | |
EA200900879A1 (ru) | Пиперидиновые агонисты gpcr | |
EA201170151A1 (ru) | Пиперидиниловые агонисты gpcr | |
NO20080052L (no) | G-Protein kopplede reseptoragonister | |
EA200900877A1 (ru) | Пиперидиновые агонисты gpcr | |
ATE557024T1 (de) | Piperidinverbindungen als gpcr-agonisten | |
ATE557023T1 (de) | Piperidinylverbindungen als gpcr-agonisten | |
NO20080010L (no) | GPCR-agonister | |
CL2008003847A1 (es) | Compuestos derivados de 6-fenilpirazin-2-carboxamida y 6-fenilpirazin-2-carbotioamida, inhibidores de dgat-1; composicion farmaceutica; y su uso en el tratamiento de la diabetes mellitus y obesidad. | |
WO2007116229A8 (en) | Heterocyclic gpcr agonists | |
NO20084380L (no) | Neuromedin U-reseptoragonister og anvendelser derav | |
ECSP12011606A (es) | Agonistas de gpr119 | |
WO2007003961A3 (en) | Gpcr agonists | |
CL2011003347A1 (es) | Composicion farmaceutica que comprende un conjugado, correspondiente a benzoato de hidrocodona ; y uso en el tratamiento de una enfermedad, trastorno o afeccion mediada por la union de un opioide a receptores opioides. | |
CY1112151T1 (el) | Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119 | |
CY1111123T1 (el) | Μεθοδοι χρησης υποδοχεα gpr119 για να πιστοποιουνται ενωσεις χρησιμες για αυξηση οστικης μαζας σε ενα ατομο | |
MY147649A (en) | Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders | |
EA201000439A1 (ru) | Бензотиазолы в качестве модуляторов рецептора грелина | |
EA201190207A1 (ru) | Соединения для лечения метаболических расстройств | |
EA201190209A1 (ru) | Соединения для лечения метаболических расстройств | |
EA201190208A1 (ru) | Соединения для лечения метаболических расстройств | |
EA201070725A1 (ru) | Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона | |
EA201270428A1 (ru) | Замещенные n-фенил-1-(4-пиридинил)-1н-пиразол-3-амины |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
TH4A | Publication of the corrected specification to eurasian patent | ||
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |